Potent strategy to inhibit HIV-1 by binding both gp120 and gp41

Ioannis Kagiampakis, Arbi Gharibi, Marie K. Mankowski, Beth A. Snyder, Roger G. Ptak, Kristabelle Alatas, Patricia J. LiWang

Research output: Contribution to journalArticle

Abstract

The development of an anti-HIV microbicide is critical in the fight against the spread of HIV. It is shown here that the covalent linking of compounds that bind gp120 with compounds that bind gp41 can inhibit HIV entry even more potently than individual inhibitors or noncovalent combinations. The most striking example involves griffithsin, a potent HIV inhibitor that binds to the surface of HIV gp120. While griffithsin inhibits HIV Env-mediated fusion in a CCR5-tropic cell-cell fusion assay with a 50% inhibitory concentration (IC 50) of 1.31 ± 0.87 nM and the gp41-binding peptide C37 shows an IC50 of 18.2 ± 7.6 nM, the covalently linked combination of griffithsin with C37 (Griff37) has an IC50 of 0.15 ± 0.05 nM, exhibiting a potency 8.7-fold greater than that of griffithsin alone. Similarly, in CXCR4-tropic cell-cell fusion assays, Griff37 is 5.2-fold more potent than griffithsin alone. In viral assays, both griffithsin and Griff37 inhibit HIV replication at midpicomolar levels, but the linked compound Griff37 is severalfold more potent than griffithsin alone against both CCR5- and CXCR4-tropic virus strains. Another example of this strategy is the covalently linked combination of peptide C37 with a variant of the gp120-binding peptide CD4M33 (L. Martin et al., Nat. Biotechnol. 21:71-76, 2003). Also, nuclear magnetic resonance (NMR) spectra for several of these compounds are shown, including, to our knowledge, the first published NMR spectrum for griffithsin.

Original languageEnglish (US)
Pages (from-to)264-275
Number of pages12
JournalAntimicrobial Agents and Chemotherapy
Volume55
Issue number1
DOIs
StatePublished - Jan 2011
Externally publishedYes

Fingerprint

HIV-1
HIV
Inhibitory Concentration 50
Cell Fusion
Magnetic Resonance Spectroscopy
HIV Envelope Protein gp120
Peptides
Anti-Infective Agents
Viruses

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Kagiampakis, I., Gharibi, A., Mankowski, M. K., Snyder, B. A., Ptak, R. G., Alatas, K., & LiWang, P. J. (2011). Potent strategy to inhibit HIV-1 by binding both gp120 and gp41. Antimicrobial Agents and Chemotherapy, 55(1), 264-275. https://doi.org/10.1128/AAC.00376-10

Potent strategy to inhibit HIV-1 by binding both gp120 and gp41. / Kagiampakis, Ioannis; Gharibi, Arbi; Mankowski, Marie K.; Snyder, Beth A.; Ptak, Roger G.; Alatas, Kristabelle; LiWang, Patricia J.

In: Antimicrobial Agents and Chemotherapy, Vol. 55, No. 1, 01.2011, p. 264-275.

Research output: Contribution to journalArticle

Kagiampakis, I, Gharibi, A, Mankowski, MK, Snyder, BA, Ptak, RG, Alatas, K & LiWang, PJ 2011, 'Potent strategy to inhibit HIV-1 by binding both gp120 and gp41', Antimicrobial Agents and Chemotherapy, vol. 55, no. 1, pp. 264-275. https://doi.org/10.1128/AAC.00376-10
Kagiampakis I, Gharibi A, Mankowski MK, Snyder BA, Ptak RG, Alatas K et al. Potent strategy to inhibit HIV-1 by binding both gp120 and gp41. Antimicrobial Agents and Chemotherapy. 2011 Jan;55(1):264-275. https://doi.org/10.1128/AAC.00376-10
Kagiampakis, Ioannis ; Gharibi, Arbi ; Mankowski, Marie K. ; Snyder, Beth A. ; Ptak, Roger G. ; Alatas, Kristabelle ; LiWang, Patricia J. / Potent strategy to inhibit HIV-1 by binding both gp120 and gp41. In: Antimicrobial Agents and Chemotherapy. 2011 ; Vol. 55, No. 1. pp. 264-275.
@article{d84f131edf3c4725a51974cadc11ae9c,
title = "Potent strategy to inhibit HIV-1 by binding both gp120 and gp41",
abstract = "The development of an anti-HIV microbicide is critical in the fight against the spread of HIV. It is shown here that the covalent linking of compounds that bind gp120 with compounds that bind gp41 can inhibit HIV entry even more potently than individual inhibitors or noncovalent combinations. The most striking example involves griffithsin, a potent HIV inhibitor that binds to the surface of HIV gp120. While griffithsin inhibits HIV Env-mediated fusion in a CCR5-tropic cell-cell fusion assay with a 50{\%} inhibitory concentration (IC 50) of 1.31 ± 0.87 nM and the gp41-binding peptide C37 shows an IC50 of 18.2 ± 7.6 nM, the covalently linked combination of griffithsin with C37 (Griff37) has an IC50 of 0.15 ± 0.05 nM, exhibiting a potency 8.7-fold greater than that of griffithsin alone. Similarly, in CXCR4-tropic cell-cell fusion assays, Griff37 is 5.2-fold more potent than griffithsin alone. In viral assays, both griffithsin and Griff37 inhibit HIV replication at midpicomolar levels, but the linked compound Griff37 is severalfold more potent than griffithsin alone against both CCR5- and CXCR4-tropic virus strains. Another example of this strategy is the covalently linked combination of peptide C37 with a variant of the gp120-binding peptide CD4M33 (L. Martin et al., Nat. Biotechnol. 21:71-76, 2003). Also, nuclear magnetic resonance (NMR) spectra for several of these compounds are shown, including, to our knowledge, the first published NMR spectrum for griffithsin.",
author = "Ioannis Kagiampakis and Arbi Gharibi and Mankowski, {Marie K.} and Snyder, {Beth A.} and Ptak, {Roger G.} and Kristabelle Alatas and LiWang, {Patricia J.}",
year = "2011",
month = "1",
doi = "10.1128/AAC.00376-10",
language = "English (US)",
volume = "55",
pages = "264--275",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Potent strategy to inhibit HIV-1 by binding both gp120 and gp41

AU - Kagiampakis, Ioannis

AU - Gharibi, Arbi

AU - Mankowski, Marie K.

AU - Snyder, Beth A.

AU - Ptak, Roger G.

AU - Alatas, Kristabelle

AU - LiWang, Patricia J.

PY - 2011/1

Y1 - 2011/1

N2 - The development of an anti-HIV microbicide is critical in the fight against the spread of HIV. It is shown here that the covalent linking of compounds that bind gp120 with compounds that bind gp41 can inhibit HIV entry even more potently than individual inhibitors or noncovalent combinations. The most striking example involves griffithsin, a potent HIV inhibitor that binds to the surface of HIV gp120. While griffithsin inhibits HIV Env-mediated fusion in a CCR5-tropic cell-cell fusion assay with a 50% inhibitory concentration (IC 50) of 1.31 ± 0.87 nM and the gp41-binding peptide C37 shows an IC50 of 18.2 ± 7.6 nM, the covalently linked combination of griffithsin with C37 (Griff37) has an IC50 of 0.15 ± 0.05 nM, exhibiting a potency 8.7-fold greater than that of griffithsin alone. Similarly, in CXCR4-tropic cell-cell fusion assays, Griff37 is 5.2-fold more potent than griffithsin alone. In viral assays, both griffithsin and Griff37 inhibit HIV replication at midpicomolar levels, but the linked compound Griff37 is severalfold more potent than griffithsin alone against both CCR5- and CXCR4-tropic virus strains. Another example of this strategy is the covalently linked combination of peptide C37 with a variant of the gp120-binding peptide CD4M33 (L. Martin et al., Nat. Biotechnol. 21:71-76, 2003). Also, nuclear magnetic resonance (NMR) spectra for several of these compounds are shown, including, to our knowledge, the first published NMR spectrum for griffithsin.

AB - The development of an anti-HIV microbicide is critical in the fight against the spread of HIV. It is shown here that the covalent linking of compounds that bind gp120 with compounds that bind gp41 can inhibit HIV entry even more potently than individual inhibitors or noncovalent combinations. The most striking example involves griffithsin, a potent HIV inhibitor that binds to the surface of HIV gp120. While griffithsin inhibits HIV Env-mediated fusion in a CCR5-tropic cell-cell fusion assay with a 50% inhibitory concentration (IC 50) of 1.31 ± 0.87 nM and the gp41-binding peptide C37 shows an IC50 of 18.2 ± 7.6 nM, the covalently linked combination of griffithsin with C37 (Griff37) has an IC50 of 0.15 ± 0.05 nM, exhibiting a potency 8.7-fold greater than that of griffithsin alone. Similarly, in CXCR4-tropic cell-cell fusion assays, Griff37 is 5.2-fold more potent than griffithsin alone. In viral assays, both griffithsin and Griff37 inhibit HIV replication at midpicomolar levels, but the linked compound Griff37 is severalfold more potent than griffithsin alone against both CCR5- and CXCR4-tropic virus strains. Another example of this strategy is the covalently linked combination of peptide C37 with a variant of the gp120-binding peptide CD4M33 (L. Martin et al., Nat. Biotechnol. 21:71-76, 2003). Also, nuclear magnetic resonance (NMR) spectra for several of these compounds are shown, including, to our knowledge, the first published NMR spectrum for griffithsin.

UR - http://www.scopus.com/inward/record.url?scp=78650647228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650647228&partnerID=8YFLogxK

U2 - 10.1128/AAC.00376-10

DO - 10.1128/AAC.00376-10

M3 - Article

C2 - 20956603

AN - SCOPUS:78650647228

VL - 55

SP - 264

EP - 275

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 1

ER -